m5717
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2017 (NCT03261401)
Timeline
Indications
Mechanism of action
- Plasmodium vivaxINHIBITOR
Plasmodium vivax inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05974267 | Phase 2 | Nov 28, 2023 | Merck KGaA |
| NCT05689047 | Phase 2 | Mar 29, 2023 | Merck KGaA |
| NCT04250363 | Phase 1 | Feb 10, 2020 | Merck KGaA |
| NCT03261401 | Phase 1 | Sep 15, 2017 | Merck KGaA |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1